CHELSEA LABS CLEARED BY FDA FOR ANDA APPROVALS
CHELSEA LABS CLEARED BY FDA FOR ANDA APPROVALS in December, the Rugby Group announced Jan. 3. Chelsea was notified by FDA in a Dec. 16 letter that the agency "will resume substantive scientific review of Chelsea's drug applications," Rugby said. Chelsea is one of two companies that reported being released from the agency's application integrity policy in December. Royce Labs announced Dec. 17 that it had re-entered FDA's ANDA review process.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth